

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 9/21/2018. The new product being launched is:

HYDROCODONE-ACETAMINOPHEN 7.5 mg-300 mg: 00527-1647-05

HYDROCODONE-ACETAMINOPHEN 10 mg-300 mg: 00527-1648-05

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 8/29/2019. The new product being launched is:

POSACONAZOLE 100 mg: 00527-2133-35

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 11/1/2018. The new product being launched is:

VARDENAFIL HCL 10 mg: 00527-2802-32

VARDENAFIL HCL 20 mg: 00527-2803-32

VARDENAFIL HCL 5 mg: 00527-2801-32

VARDENAFIL HCL 2.5 mg: 00527-2800-32

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 2/2/2021. The new product being launched is:

CHLORPROMAZINE HCL 25 mg: 00527-2962-43

CHLORPROMAZINE HCL 50 mg: 00527-2963-43

CHLORPROMAZINE HCL 100 mg: 00527-2964-43

CHLORPROMAZINE HCL 200 mg: 00527-2965-43

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 8/11/2020. The new product being launched is:

LEVORPHANOL TARTRATE 2 mg: 00527-3236-37

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 1/21/2021. The new product being launched is:

LEVORPHANOL TARTRATE 3 mg: 00527-3237-37

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 3/19/2019. The new product being launched is:

ESOMEPRAZOLE MAGNESIUM 20 mg: 62175-0820-43

Sincerely,

John Whitridge

Manager

Advisory

9/3/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Lannett Company, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 3/15/2019. The new product being launched is:

ESOMEPRAZOLE MAGNESIUM 40 mg: 62175-0840-43

Sincerely,

John Whitridge

Manager

Advisory